Marketing-authorisation holder
Mankind Pharma
3 medicines in 1 country, as authorisation holder and manufacturer.
Medicines
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| REVEFENACIN175mcg/3ml · Solution | Revefenacin | United States | tentative | 2025 |
| SITAGLIPTIN100mg | 25mg | 50mg · Tablet | Sitagliptin | United States | tentative | 2024 |
| SITAGLIPTIN AND METFORMIN HCL1000mg | 1000mg er tablet | 100mg base tablet | 500mg | 50mg · Tablet | Sitagliptin, Metformin | United States | tentative | 2024 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 0 | 3 | CompaniesAll medicines |
Also in the registers of Brazil
Top substances
The active substances in most of its medicines.
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- mankind
- mankind pharma limited
- mankind pharma ltd
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 3
- Countries
- 1
- Roles
- Authorisation holder and manufacturer